Search IconSearch
November 28, 2022/Cancer

Infectious Disease Protections for Patients with Cancer

A Q&A with infectious disease expert Eric Cober, MD


When it comes to infection control, protecting patients undergoing cancer treatment can seem like a moving target. Emerging COVID-19 variants, respiratory syncytial virus (RSV) outbreaks and growing flu cases are spurring a host of questions from clinicians looking to safeguard their patients. Today ConsultQD sat down with Eric Cober, MD, to discuss strategies for helping patients stay healthy during cancer treatment.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

What are some of the biggest infectious disease concerns that you have currently for patients who have cancer?

Right now, the biggest concerns are respiratory viruses such as COVID-19. We’re also entering influenza and RSV season as well, which even before the time of SARS was a difficult illness for many cancer patients, especially those who have undergone stem cell transplants.

With many mask mandates being removed, what should clinicians recommend their patients do to protect themselves?

There are multiple things patients can do to reduce their risk. Avoid large gatherings in close, indoor spaces, especially during flu and RSV season. Continue to wear a good-quality surgical mask. Get vaccinated and stay up to date on all your boosters.

When it comes to infection concerns, do you think we’ll ever get to a point where things return to “normal” for patients who have cancer?

In a sense there hasn’t been a “normal” for those undergoing treatment. Patients have always had to be careful to protect themselves from respiratory viruses, and now we have COVID-19 to add to that list.

When you think about advising patients, it’s all about risk stratification. If a patient hangs out at a bar for a few hours when there’s a COVID spike, there’s a high likelihood of getting COVID. If they stay home and don’t have visitors, they’re not likely to get it, but everyone has to make their own value judgments on where they fit on that spectrum of risk. For anyone with an active malignancy or who had a stem cell transplant within the last year or two, I’d advise them to be conservative on that spectrum because they are at risk of more severe outcomes with COVID.


Recent reports show fewer than 10% of people in the US have received the bivalent booster. What advice would you have for physicians looking to encourage their patients to get boosted?

Focus on the individual patient and the fact that as someone with cancer, they’re more susceptible than the general population. Unless they’ve personally experienced adverse side effects, it’s worth it to get the shot. You can try to build from there by encouraging the patient’s loved ones to get boosted. It’s not perfect protection but it’s better than not having it.

Do you recommend patients with cancer get EVUSHELD antibody treatment as a preventative measure?

EVUSHELD offers some protection, though an estimated 45% of the circulating variants are resistant to it. As of today, the National Institutes of Health is still recommending EVUSHELD, though this may change if the percentage of variants that are resistant to it increases.

Do you recommend that patients get antibody tests for COVID-19?

Probably not. Most of the commercially available tests can measure COVID-19 antibodies but they don’t give you a sense of how well those antibodies would neutralize COVID. In other words, there’s currently no way to know how the volume of antibodies a person has correlates to what protection they have against the virus.

In terms of influenza, how do you determine which flu shot a patient should receive?

Some cancer centers will give high-dose inactivated influenza vaccines to any patient who is immune compromised. At Cleveland Clinic we generally follow age labeling, which means those who are 65 or older receive the high-dose inactivated vaccine and anyone else gets the standard quadrivalent inactivated vaccine.

In terms of timing, should clinicians recommend their patients wait to get their flu shot until we’re further into flu season?

Ideally, I recommend getting the flu vaccine as soon as it’s available. There were already considerable cases of flu in early October this year. I generally advise not to try to “game” the system by waiting. The efficacy may wane a bit at the end of the season but we don’t know by how much, and generally we do not recommend getting a second flu shot at the end of the season.

What do you say to clinicians whose patients are worried about contracting mpox (monkeypox)?

Mpox (monkeypox) has a very specific set of risk factors, and there is very little risk to the general population right now. The predominant mode of transmission currently is through intimate sexual contact between men. If you have a patient with cancer who is in this category and isn’t in a mutually monogamous relationship, they would be at increased risk. You can reach out to us for information about the possibility of getting the vaccine.

Have polio outbreaks changed the recommendations for vaccines for stem cell transplant recipients?

No. The overall risk of contracting polio is quite low, but the inactivated polio vaccine has been part of our stem cell transplant vaccination protocol.

In general, what advice do you have in terms of timing of patients with cancer receiving vaccines?

Indicated vaccines should be given before initiation of chemotherapy or immunosuppression whenever possible. I generally avoid giving vaccines to patients actively receiving chemotherapy because of reduced efficacy. That being said, it is safe to receive the COVID-19 and influenza vaccinations while receiving chemotherapy, and may even be advisable, given the need to protect against the circulating virus.


For live vaccines such as MMR and varicella (chicken pox) are contraindicated in patients with ongoing immunocompromise.

What are some good resources clinicians can use to stay up to date about infection protection?

The CDC web page Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States is usually the single best source of information for physician questions regarding COVID vaccines . Also, the CDC’s COVID data tracker is updated weekly, and gives you a sense of what the circulating variants in your area are.

Editor’s Note: In November 2022, the World Health Organization and the U.S. Centers for Disease Control and Prevention renamed the monkeypox virus “mpox.” We have updated some language in this article to reflect that change.


Related Articles

Dr. Grobmyer and team
June 14, 2024/Cancer/Innovations
Fatima bint Mubarak Center Addresses Inequities in Cancer Care

Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

car T-cells
June 3, 2024/Cancer/Research
CAR T-Cell Treatment Offers Hope for Richter Transformation

Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel

Blood clot
May 17, 2024/Cancer/Research
Managing the Risks of Venous Thromboembolisms in Patients with Cancer

Oral anticoagulants may be beneficial but need to be balanced against bleeding risks

Director of the Novel Cancer Therapeutics Center
May 2, 2024/Cancer/Innovations
Oncology Pharmacovigilance Clinic Expands Specialties

First-of-its-kind clinic for immune-related adverse events supports oncologists in managing severe side effects

Scrambler therapy for nerve pain
April 29, 2024/Cancer
Scrambler Technology Life Changing for Many Patients with Neuropathic Pain

Novel therapy “retrains” the brain to disrupt pain signals